Clinical treatment of advanced Merkel cell carcinoma

晚期默克尔细胞癌的临床治疗

• 批准号: 8938129
• 负责人: Isaac Brownell
• 金额: $ 13.32万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8938129
• 关键词: Antibodies; Biological Assay; Blood specimen; Clinical; Clinical Research; Clinical Treatment; Clinical Trials Design; Enrollment; Goals; Immune response; Immunotherapy; Merkel cell carcinoma; Patients; Pharmaceutical Preparations; Protocols documentation; Reporting; Sampling; Site; Staging; United States National Institutes of Health; effective therapy; open label; phase 2 study; tumor

Patients will be enrolled in clinical trials designed to treat patients with advanced Merkel cell carcinoma (stage 3b or 4). We seek to have the NIH Clinical Research Center serve as a study site in multi-institutional drug trials. Currently approval is being sought to participate in an open-label phase II study of EMD Serono's anti PD-L1 antibody for the treatment of Merkel cell carcinoma. In addition to the samples collected during the trial for the central protocol, patients seen at the NIH will have additional tumor specimens and blood collected to evaluate anti-tumor immune responses during treatment.

患者将参加旨在治疗晚期默克尔细胞癌患者的临床试验（第3B期或4阶段）。我们寻求将NIH临床研究中心作为多机构药物试验的研究地点。目前正在寻求批准参加EMD Serono的抗PD-L1抗体的开放标签II期研究，用于治疗Merkel细胞癌。除了在试验中为中央议定书中收集的样品外，在NIH中看到的患者还会有其他肿瘤标本和血液收集的血液，以评估治疗过程中抗肿瘤免疫反应。